CriticalSelective serotonin reuptake inhibitors (SSRIs)×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Sertraline selectively inhibits serotonin reuptake, and with drugs that affect serotonin metabolism, MAO inhibitors included, its risk of serotonin syndrome and neuroleptic malignant syndrome rises (sertraline SmPC, AEMPS). MAO activity recovers 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine label, US Food and Drug Administration, FDA). The mean elimination half-life of sertraline is about 26 hours (sertraline SmPC, AEMPS).
Symptoms
Serotonin syndrome with tranylcypromine and sertraline can be severe and life-threatening (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The sertraline SmPC reports tremor, myoclonus, sweating, nausea, vomiting, flushing, dizziness, hyperthermia with features of neuroleptic malignant syndrome, seizures and death in people who started sertraline soon after stopping a monoamine oxidase inhibitor, or started the inhibitor soon after stopping sertraline (sertraline SmPC, AEMPS). Serotonin syndrome shows as mental changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high temperature), neuromuscular signs (tremor, rigidity, myoclonus, overactive reflexes), seizures and nausea, vomiting or diarrhoea (sertraline label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish sertraline summary of product characteristics (SmPC) contraindicates it with irreversible monoamine oxidase inhibitors (MAOIs), the group tranylcypromine belongs to, and the Spanish tranylcypromine SmPC rules out its use with all selective serotonin reuptake inhibitors (sertraline and tranylcypromine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US sertraline and tranylcypromine labels also contraindicate the combination (sertraline and tranylcypromine labels, US Food and Drug Administration, FDA). Start sertraline at least 14 days after stopping tranylcypromine (sertraline SmPC, AEMPS, and FDA label; tranylcypromine SmPC, AEMPS). Before starting tranylcypromine, stop sertraline at least 7 days earlier under the Spanish sertraline SmPC (AEMPS), or at least 14 days earlier under the US label (sertraline FDA label). The Spanish tranylcypromine SmPC recommends a gap of about 5 half-lives of sertraline and its active metabolites (tranylcypromine SmPC, AEMPS). If serotonin syndrome develops, stop sertraline and other serotonergic drugs at once and start supportive symptomatic treatment (sertraline FDA label). Treat severe serotonin syndrome caused by an interaction with serotonergic drugs as tranylcypromine poisoning: in intensive care, with monitoring of pulse, blood pressure, breathing and temperature, and with mechanical ventilation available (tranylcypromine SmPC, AEMPS, overdose section). The same SmPC recommends benzodiazepines for severe agitation or marked muscle rigidity. Oral cyproheptadine may be tried to block serotonin receptors. At a temperature of 40 °C or higher, start active cooling at once (tranylcypromine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zoloft (sertraline hydrochloride) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid fda754f6-d0f3-4dce-a17a-927d64f912f7, revised 08/2023, sections 4, 5.2 and 7.1
- AEMPS: Ficha técnica: Besitran (sertralina) (nº registro 59717), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59717, revisión 08/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1